Author:
Romano Antonietta,Angeli Paolo,Piovesan Sara,Noventa Franco,Anastassopoulos Georgios,Chemello Liliana,Cavalletto Luisa,Gambato Martina,Russo Francesco Paolo,Burra Patrizia,Vincenzi Valter,Scotton Pier Giorgio,Panese Sandro,Tempesta Diego,Bertin Tosca,Carrara Maurizio,Carlotto Antonio,Capra Franco,Carolo Giada,Scroccaro Giovanna,Alberti Alfredo
Reference40 articles.
1. Hepatitis C virus infection;Manns;Nat Rev Dis Primers,2017
2. New hepatitis C therapies: the toolbox, strategies, and challenges;Pawlotsky;Gastroenterology,2014
3. For the ASTRAL-1 Investigators Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection;Feld;N Engl J Med,2015
4. Safety and efficacy of Elbasvir/Grazoprevir in patients with Hepatitis C, Virus infection and compensated cirrhosis: an Integrated Analysis;Jacobson;Gastroenterology,2017
5. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort;Welzel;Gut,2016